Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in Recurrent Rectal Cancer
Key facts
- Who runs it
- Washington University School of Medicine
- Where
- St Louis, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 15 people enrolled
- Started
- 4 May 2021
- Ended
- 18 Nov 2024
- Type of study
- Interventional, 4 groups
- Treatments tested
- Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy
- MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Record updated
- 29 September 2025
- Why it stopped
- Slow enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- History of biopsy-proven adenocarcinoma of the rectum, anus or rectosigmoid junction of any stage now with recurrent disease in the pelvis
- One prior course of radiation therapy to the pelvis for rectal cancer
- ECOG performance status 0-2
- At least 18 years of age
- Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
- Able to understand and willing to sign an IRB-approved written informed consent document
Who cannot take part
- More than one prior course of radiation to the pelvis for rectal cancer
- Prior radiation to the pelvis for disease other than rectal cancer
- Tumor in the rectum/colon requiring radiation therapy to the full circumference of the rectum/colon
- Current treatment with any investigational agents
- Patients with pre-existing radiosensitizing conditions, such as connective tissue disorders (i.e. lupus, scleroderma) and genetic mutations (i.e. ataxia-telangiectasia)
- A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence of disease, basal cell or squamous cell carcinoma of the skin that were treated with local resection only, or carcinoma in situ of the cervix. Patients with history of prostate cancer treated without radiotherapy and no evidence of disease are eligible
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or unstable angina pectoris
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days of study entry
Where in United States
- Washington University School of MedicineSt Louis, United States
About the trial
What the trial wants to find out
The purpose of this trial is to determine the maximum tolerated dose (MTD) of hypofractionated IMPT for the reirradiation of locoregionally recurrent rectal cancer.
The 4 groups in the trial
- Dose Level 1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested
* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 1 (30 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).
Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Dose Level 2: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested
* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 2 (35 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).
Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Dose Level 3: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested
* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level 3 (40 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).
Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
- Dose Level -1: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT)Treatment being tested
* Radiotherapy will consist of five fractions, delivered once daily, with pencil beam scanning proton beam therapy using the defined dose in dose level -1 (25 Gy). * The use of Intensity Modulated Radiation Therapy (IMRT) with photon beam therapy is permitted at the discretion of the treating investigator in order to avoid extended treatment delays due to logistical reasons (e.g. machine downtime).
Treatment: Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy and MEVION S250i Hyperscan and Adaptive Aperture Proton Therapy Machine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer - IMPARC
- Record updated
- 29 September 2025